248 related articles for article (PubMed ID: 29047108)
21. Cd20 Expression and Effects on Outcome of Relapsed/ Refractory Diffuse Large B Cell Lymphoma after Treatment with Rituximab.
Rasheed AA; Samad A; Raheem A; Hirani SI; Shabbir- Moosajee M
Asian Pac J Cancer Prev; 2018 Feb; 19(2):331-335. PubMed ID: 29479962
[TBL] [Abstract][Full Text] [Related]
22. Hepatitis C virus - Associated marginal zone lymphoma.
Armand M; Besson C; Hermine O; Davi F
Best Pract Res Clin Haematol; 2017; 30(1-2):41-49. PubMed ID: 28288715
[TBL] [Abstract][Full Text] [Related]
23. Efficacy and prognosis of antiviral therapy on hepatitis C following treatment of lymphoma in HCV-positive diffuse large-cell lymphoma.
Tsutsumi Y; Nakayama C; Kamada K; Kikuchi R; Kudo D; Ito S; Matsuoka S; Shiratori S; Yamamoto Y; Naruse H; Teshima T
Ann Hematol; 2017 Dec; 96(12):2057-2061. PubMed ID: 28939993
[TBL] [Abstract][Full Text] [Related]
24. Antiviral therapies for managing viral hepatitis in lymphoma patients.
Merli M; Rattotti S; Gotti M; Arcaini L
Expert Opin Pharmacother; 2017 Mar; 18(4):363-376. PubMed ID: 28140702
[TBL] [Abstract][Full Text] [Related]
25. New risk factors and new tendency for central nervous system relapse in patients with diffuse large B-cell lymphoma: a retrospective study.
Cai QQ; Hu LY; Geng QR; Chen J; Lu ZH; Rao HL; Liu Q; Jiang WQ; Huang HQ; Lin TY; Xia ZJ
Chin J Cancer; 2016 Sep; 35(1):87. PubMed ID: 27624700
[TBL] [Abstract][Full Text] [Related]
26. Lenalidomide in Relapsed or Refractory Diffuse Large B-Cell Lymphoma: Is It a Valid Treatment Option?
Mondello P; Steiner N; Willenbacher W; Ferrero S; Ghione P; Marabese A; Pitini V; Cuzzocrea S; Mian M
Oncologist; 2016 Sep; 21(9):1107-12. PubMed ID: 27382029
[TBL] [Abstract][Full Text] [Related]
27. Lymphomas associated with chronic hepatitis C virus infection: A prospective multicenter cohort study from the Rete Ematologica Lombarda (REL) clinical network.
Rattotti S; Ferretti VV; Rusconi C; Rossi A; Fogazzi S; Baldini L; Pioltelli P; Balzarotti M; Farina L; Ferreri AJM; Laszlo D; Speziale V; Varettoni M; Sciarra R; Morello L; Tedeschi A; Frigeni M; Defrancesco I; Zerbi C; Flospergher E; Nizzoli ME; Morra E; Arcaini L;
Hematol Oncol; 2019 Apr; 37(2):160-167. PubMed ID: 30726562
[TBL] [Abstract][Full Text] [Related]
28. Clinical outcome in diffuse large B-cell lymphoma with hepatitis C virus infection in the rituximab era: a single center experience.
Nishikawa H; Tsudo M; Osaki Y
Oncol Rep; 2012 Sep; 28(3):835-40. PubMed ID: 22736295
[TBL] [Abstract][Full Text] [Related]
29. Lymphoma recurrence 5 years or later following diffuse large B-cell lymphoma: clinical characteristics and outcome.
Larouche JF; Berger F; Chassagne-Clément C; Ffrench M; Callet-Bauchu E; Sebban C; Ghesquières H; Broussais-Guillaumot F; Salles G; Coiffier B
J Clin Oncol; 2010 Apr; 28(12):2094-100. PubMed ID: 20308668
[TBL] [Abstract][Full Text] [Related]
30. CD5 positivity is an independent adverse prognostic factor in elderly patients with diffuse large B cell lymphoma.
Chuang WY; Chang H; Shih LY; Wang PN; Chang YS; Lin TL; Hung YS; Yeh CJ; Ueng SH; Tang TC; Kuo MC; Dunn P; Wu JH; Kao HW; Ou CW; Wan YL; Hsueh C
Virchows Arch; 2015 Nov; 467(5):571-82. PubMed ID: 26369546
[TBL] [Abstract][Full Text] [Related]
31. Ocular adnexal diffuse large B-cell lymphoma: a multicenter international study.
Munch-Petersen HD; Rasmussen PK; Coupland SE; Esmaeli B; Finger PT; Graue GF; Grossniklaus HE; Honavar SG; Khong JJ; McKelvie PA; Mulay K; Prause JU; Ralfkiaer E; Sjö LD; Sniegowski MC; Vemuganti GK; Heegaard S
JAMA Ophthalmol; 2015 Feb; 133(2):165-73. PubMed ID: 25393033
[TBL] [Abstract][Full Text] [Related]
32. [Clinicopathological features of Epstein-Barr virus-positive diffuse large B-cell lymphoma in elderly].
Xu FP; Liu YH; Zhuang HG; Luo DL; Li L; Zhang F; Luo XL; Du X; Li WY; Chen Q
Zhonghua Bing Li Xue Za Zhi; 2011 Sep; 40(9):616-21. PubMed ID: 22177246
[TBL] [Abstract][Full Text] [Related]
33. [The Current Status and Research Progress of Antiviral Therapy in HCV-Associated Lymphoma --Review].
Sun XH; Wan S; Li ZJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Dec; 29(6):1987-1990. PubMed ID: 34893147
[TBL] [Abstract][Full Text] [Related]
34. [Retrospective analysis of the clinical features and prognostic factors of 370 patients with advanced-stage diffuse large B-cell lymphoma].
Han Y; Qin Y; He XH; Yang JL; Liu P; Zhang CG; Zhou LQ; Zhou SY; Gui L; Song YW; Sun Y; Shi YK
Zhonghua Zhong Liu Za Zhi; 2018 Jun; 40(6):456-461. PubMed ID: 29936773
[No Abstract] [Full Text] [Related]
35. Clinical outcome of HCV-positive patients with diffuse large B-cell lymphoma treated with rituximab-based chemotherapy.
Salah-Eldin MA; Ebrahim MA; El-Sadda W
Ann Hematol; 2014 Nov; 93(11):1903-11. PubMed ID: 24951125
[TBL] [Abstract][Full Text] [Related]
36. Role of hepatitis C virus infection in malignant lymphoma in Spain.
de Sanjose S; Nieters A; Goedert JJ; Domingo-Domenech E; Fernandez de Sevilla A; Bosch R; Herrera P; Domingo A; Petit J; Bosch X; Kallinowski B
Int J Cancer; 2004 Aug; 111(1):81-5. PubMed ID: 15185347
[TBL] [Abstract][Full Text] [Related]
37. Hepatitis C reactivation in patients who have diffuse large B-cell lymphoma treated with rituximab: a case report and review of literature.
Nooka A; Shenoy PJ; Sinha R; Lonial S; Flowers CR
Clin Lymphoma Myeloma Leuk; 2011 Oct; 11(5):379-84. PubMed ID: 21729690
[TBL] [Abstract][Full Text] [Related]
38. Concomitant therapy with direct-acting antivirals and chemoimmunotherapy in HCV-associated diffuse large B-cell lymphoma.
Occhipinti V; Farina L; Viganò M; Capecchi M; Labanca S; Fanetti I; Corradini P; Rumi M
Dig Liver Dis; 2019 May; 51(5):719-723. PubMed ID: 30502232
[TBL] [Abstract][Full Text] [Related]
39. Lymphopenia assessed during routine follow-up after immunochemotherapy (R-CHOP) is a risk factor for predicting relapse in patients with diffuse large B-cell lymphoma.
Porrata LF; Rsitow K; Inwards DJ; Ansell SM; Micallef IN; Johnston PB; Habermann TM; Witzig TE; Colgan JP; Nowakowski GS; Thompson CA; Markovic SN
Leukemia; 2010 Jul; 24(7):1343-9. PubMed ID: 20485372
[TBL] [Abstract][Full Text] [Related]
40. MicroRNA as potential biomarker in HCV-associated diffuse large B-cell lymphoma.
Augello C; Gianelli U; Savi F; Moro A; Bonoldi E; Gambacorta M; Vaira V; Baldini L; Bosari S
J Clin Pathol; 2014 Aug; 67(8):697-701. PubMed ID: 24914240
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
